Acasti Pharma Stock Current Valuation
| ACSTDelisted Stock | USD 3.37 0.01 0.30% |
Valuation analysis of Acasti Pharma helps investors to measure Acasti Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Acasti Pharma's price fluctuation is very risky at this time. Calculation of the real value of Acasti Pharma is based on 3 months time horizon. Increasing Acasti Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Acasti Pharma's intrinsic value may or may not be the same as its current market price of 3.37, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.37 | Real 2.61 | Hype 3.2 | Naive 3.28 |
The intrinsic value of Acasti Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Acasti Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Acasti Pharma helps investors to forecast how Acasti stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Acasti Pharma more accurately as focusing exclusively on Acasti Pharma's fundamentals will not take into account other important factors: Acasti Pharma Company Current Valuation Analysis
Acasti Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Acasti Pharma Current Valuation | 11.17 M |
Most of Acasti Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acasti Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, Acasti Pharma has a Current Valuation of 11.17 M. This is 99.92% lower than that of the Pharmaceuticals sector and 99.76% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.93% higher than that of the company.
Acasti Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acasti Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acasti Pharma could also be used in its relative valuation, which is a method of valuing Acasti Pharma by comparing valuation metrics of similar companies.Acasti Pharma is currently under evaluation in current valuation category among its peers.
Acasti Fundamentals
| Return On Equity | -0.19 | |||
| Return On Asset | -0.12 | |||
| Current Valuation | 11.17 M | |||
| Shares Outstanding | 10.14 M | |||
| Shares Owned By Insiders | 38.39 % | |||
| Shares Owned By Institutions | 21.22 % | |||
| Number Of Shares Shorted | 154.19 K | |||
| Price To Earning | 15.34 X | |||
| Price To Book | 0.58 X | |||
| Price To Sales | 208.39 X | |||
| Gross Profit | 120 K | |||
| EBITDA | (11.3 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 38.39 M | |||
| Cash Per Share | 0.86 X | |||
| Total Debt | 11.56 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 11.13 X | |||
| Book Value Per Share | 5.86 X | |||
| Cash Flow From Operations | (12.33 M) | |||
| Short Ratio | 3.84 X | |||
| Earnings Per Share | (1.43) X | |||
| Target Price | 7.97 | |||
| Beta | 1.52 | |||
| Market Capitalization | 36.5 M | |||
| Total Asset | 73.3 M | |||
| Retained Earnings | (211.12 M) | |||
| Working Capital | 22.33 M | |||
| Current Asset | 11.33 M | |||
| Current Liabilities | 1.14 M | |||
| Net Asset | 73.3 M |
About Acasti Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acasti Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acasti Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acasti Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Acasti Stock
If you are still planning to invest in Acasti Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acasti Pharma's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |